SUPN Supernus, Inc.

28.35USD-2.11%Mkt Cap: 5.89B USDP/E: —

Supernus, Inc., together with its subsidiaries, engages in the development, manufacture, and sale of buprenorphine-based prescription drugs for the treatment of opioid dependence and related disorders in the United State…

Insiders, last 90 days1 buy
Institutional holders20 on file

Key Statistics

Company
Market Cap5.89B USD
Enterprise Value3.61B USD
Revenue (TTM)1.37B USD
Gross Profit644.39M USD
Net Income (TTM)-38.55M USD
Revenue/Share11.26 USD
Last Price28.35 USD
Fiscal Year EndDec 2025
MR QuarterSep 2026
Employees827
CountryUS
SectorHealthcare
IndustryDrug Manufacturers - Specialty & Generic
ISIN—
Valuation
P/E (Trailing)—
P/E (Forward)7.08
PEG—
EV/EBITDA5.54
EV/Revenue2.63
P/S4.29
P/B-55.81
EPS (TTM)-0.76 USD
EPS (Forward)3.95 USD
52W Range
25.927% of range59.68
52W High59.68 USD
52W Low25.92 USD
Profitability
Gross Margin89.63%
Oper. Margin46.94%
EBITDA Margin47.45%
Profit Margin-5.36%
ROE-3.63%
ROA-2.65%
ROIC-3.65%
ROCE-3.31%
Growth
Revenue Growth13.40%
Earnings Growth239.40%
Cash Flow & Leverage
Operating CF47.33M USD
CapEx (TTM)1.34M USD
FCF Margin16.53%
FCF Yield3.86%
Net Debt196.00M USD
Net Debt/EBITDA0.30
Net Debt/FCF0.86
Balance Sheet
Debt/Equity0.04
Current Ratio0.61
Quick Ratio0.45
Book Value/Sh-0.51 USD
Cash/Share2.58 USD
Dividends
Fwd Div Rate—
Trail. Div Rate0.00 USD
Div. Yield0.00%
5Y Avg Yield—
Payout Ratio0.00%
Ex-Div Date—
Pay DateNov 6, 2026
Analyst Consensus
Rating1.3 (Strong Buy)
Strong BuyBuyHoldSellStr. Sell
Target (Mean)54.14 USD
Upside (mean)+91.0%
Target Range45.00 USD – 87.00 USD
45.00+91.0% to mean87.00
# Analysts7
Ownership
Shares Out.207.72M
Float114.74M
Insiders2.06%
Institutions61.24%
Short Interest
Short Ratio4.3d
Short % Float9.72%
Short % Out.7.93%
Shares Short4.62M
Short (prev mo.)4.99M
Technical
SMA 5033.79 (-16.1%)
SMA 20035.40 (-19.9%)
Beta1.13
S&P 52W Chg12.08%
Avg Vol (30d)2.34M
Avg Vol (10d)4.80M
Technical Indicators
RSI (14)30.3
MACD-3.2898
MACD Signal-3.3063
MACD Hist.+0.0165
BB Upper45.71 USD
BB Middle32.93 USD
BB Lower20.14 USD
BB Width77.66%
ATR (14)1.942 USD
Vol Ratio (20d)0.82x

About Supernus (NASDAQ: SUPN)

›

Supernus (NASDAQ: SUPN) is listed on Nasdaq, where its shares trade in USD. It belongs to the Drug Manufacturers - Specialty & Generic industry, part of the Healthcare sector, and reports about 827 employees.

The shares were at 28.35 USD on 19 November 2026, down 50.3% over 52 weeks. Its 52-week range is 25.92 USD to 59.68 USD: the price is 52.5% below the high and 9.4% above the low.

Its market capitalisation is 5.89B USD.

Supernus reports return on equity of -3.6%, an operating margin of 46.9% and revenue up 13.4% year over year.

Its debt exceeds its cash by 196.00M USD, a debt-to-equity ratio of 0.04. Its Piotroski F-score is 4 out of 9, an average reading of its financial health. 7 analysts cover the stock, with an average rating of Strong Buy; their mean price target of 54.14 USD is 91.0% above the current price. The next earnings report is expected on 23 February 2027.